Fallopian Tube Access Diagnostics

Fallopian tube access diagnostics is the [[NVisionMedical|nVision Medical]] product thesis in Surbhi Sarna, Founder of nVision Medical. Surbhi Sarna argues that if many ovarian cancers originate in the fallopian tube, then diagnostic progress may depend on collecting cells from that hard-to-reach location without surgical access.

The technical difficulty is central. Sarna describes the fallopian tube as narrow, twisting, and usually collapsed unless pressurized. The device therefore used a self-navigating catheter with a linear everting balloon that could unfold into the tube, collect cells, and retract into a sheath to reduce contamination.

The concept is a medical-device version of Hard Problem MVP Scoping. The first goal was not to solve all women’s-health diagnostics at once, but to create a safe access and cell-collection route that physicians could use and that Medical Device Clinical Validation could support.

Key Claims

• A diagnostic product may need to solve access before it can solve detection.
• The device has to be designed around real anatomy, hand use, screen use, contamination risk, and physician workflow.
• Site-of-origin reasoning can turn a broad cancer-screening ambition into a narrower technical target.
• Regulatory and clinical validation decide whether the access route becomes a usable medical claim rather than only an elegant mechanism.

Connections

• [[NVisionMedical|nVision Medical]], Surbhi Sarna, and [[CindyDAmicus|Cindy D’Amicus]] - source company, founder, and advisor context.
• Ovarian Cancer Diagnostics, Women’s Health Diagnostic Gap, Physician-Led Medical Device Design, and Medical Device Clinical Validation - diagnostic, design, and evidence branch.
• Medical Risk Management, Hard Problem MVP Scoping, Hard Tech Fundraising, and [[FoodAndDrugAdministration|FDA]] - safety, startup scoping, fundraising, and regulation context.